AVEO Pharmaceuticals Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVEO Pharmaceuticals stock.
View analyst ratings for AVEO Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given AVEO Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVEO Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for AVEO Pharmaceuticals.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. The biopharmaceutical company earned $7.56 million during the quarter, compared to analyst estimates of $7.76 million. AVEO Pharmaceuticals had a negative net margin of 398.34% and a negative trailing twelve-month return on equity of 107.25%.
View AVEO Pharmaceuticals' earnings history.

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVEO shares have increased by 93.1% and is now trading at $6.74.
View which stocks have been most impacted by COVID-19.

Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

3 analysts have issued twelve-month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $9.00 to $19.00. On average, they expect AVEO Pharmaceuticals' share price to reach $15.33 in the next year. This suggests a possible upside of 127.5% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals or view top-rated stocks among Wall Street analysts.

4 employees have rated AVEO Pharmaceuticals CEO Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among AVEO Pharmaceuticals' employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of AVEO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

AVEO Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.21%), Opaleye Management Inc. (1.88%), BlackRock Inc. (1.39%), Goldman Sachs Group Inc. (1.00%), Susquehanna International Group LLP (0.00%) and Geode Capital Management LLC (0.71%). Company insiders that own AVEO Pharmaceuticals stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals.

AVEO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Opaleye Management Inc., Northern Trust Corp, Geode Capital Management LLC, Morgan Stanley, Morgan Stanley, and Citadel Advisors LLC.
View insider buying and selling activity for AVEO Pharmaceuticals or view top insider-selling stocks.

AVEO stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Ergoteles LLC, Renaissance Technologies LLC, Simplex Trading LLC, Vanguard Group Inc., Susquehanna Fundamental Investments LLC, Jump Financial LLC, and Tibra Equities Europe Ltd. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Michael Ferraresso, Michael P Bailey, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals or or view top insider-buying stocks.

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVEO stock can currently be purchased for approximately $6.74.

AVEO Pharmaceuticals has a market capitalization of $231.68 million and generates $6.02 million in revenue each year. The biopharmaceutical company earns $-35,580,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

AVEO Pharmaceuticals employs 94 workers across the globe.

AVEO Pharmaceuticals was founded in 2001.

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

AVEO Pharmaceuticals is headquartered at 30 WINTER STREET, BOSTON MA, 02108.

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at (617) 400-0101 or via email at [email protected].